Bartoshuk LM, Duffy VB, Hayes JE, Moskowitz HR, Snyder DJ Psychophysics of sweet and fat perception in obesity: problems, solutions and new perspectives. Philos Trans R Soc Lond B Biol Sci. 2006 Jul 29;361(1471):1137-48. Review.
Bartoshuk LM, Duffy VB, Miller IJ PTC/PROP tasting: anatomy, psychophysics, and sex effects. Physiol Behav. 1994 Dec;56(6):1165-71. Review. Erratum in: Physiol Behav 1995 Jul;58(1):203.
Drewnowski A Taste preferences and food intake. Annu Rev Nutr. 1997;17:237-53. Review.
Duffy VB, Chapo AK Smell, Taste, and Somatosensation in the Elderly. Jones and Bartlett Publishers, 2006: 115-153.
Duffy VB Associations between oral sensation, dietary behaviors and risk of cardiovascular disease (CVD). Appetite. 2004 Aug;43(1):5-9. Review.
Goldstein GL, Daun H, Tepper BJ Adiposity in middle-aged women is associated with genetic taste blindness to 6-n-propylthiouracil. Obes Res. 2005 Jun;13(6):1017-23.
He W, Sengupta M, Velkoff VA, DeBarros KA U.S. Census Bureau, Current Population Reports, 65+ in the United States: 2005. U.S. Government Printing Office, Washington DC. 2005: 23-209.
Lanier SA, Hayes JE, Duffy VB Sweet and bitter tastes of alcoholic beverages mediate alcohol intake in of-age undergraduates. Physiol Behav. 2005 Jan 17;83(5):821-31. Epub 2004 Nov 21.
Rolls BJ Do chemosensory changes influence food intake in the elderly? Physiol Behav. 1999 Apr;66(2):193-7. Review.
Seiberling KA, Conley DB Aging and olfactory and taste function. Otolaryngol Clin North Am. 2004 Dec;37(6):1209-28, vii. Review.
Vega-López S, Ausman LM, Griffith JL, Lichtenstein AH Interindividual variability and intra-individual reproducibility of glycemic index values for commercial white bread. Diabetes Care. 2007 Jun;30(6):1412-7. Epub 2007 Mar 23.
Relationship Between Variations in Taste Perception and Chronic Disease Risk Factors as a Function of Age
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
